Submitted:
15 April 2024
Posted:
19 April 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
3. Discussion
4. Materials and Methods
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- L. Rodriguez, B. Bustamante, L. Huaroto, C. Agurto, R. Illescas, R. Ramirez, A. Diaz, J. Hidalgo, A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes, PLoS One 12 (2017) e0175172. [CrossRef]
- J. Ainsworth, P. Sewell, S. Eggert, K. Morris, S. Pillai, Fungal Infections Are Not Associated with Increased Mortality in COVID-19 Patients Admitted to Intensive Care Unit (ICU), Crit Care Res Pract 2023 (2023) 4037915. [CrossRef]
- Z. Zhang, R. Zhu, Z. Luan, X. Ma, Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis, BMJ Open 10 (2020) e036452. [CrossRef]
- M. Bassetti, D.R. Giacobbe, A. Vena, C. Trucchi, F. Ansaldi, M. Antonelli, V. Adamkova, C. Alicino, M.P. Almyroudi, E. Atchade, A.M. Azzini, N. Carannante, A. Carnelutti, S. Corcione, A. Cortegiani, G. Dimopoulos, S. Dubler, J.L. García-Garmendia, M. Girardis, O.A. Cornely, S. Ianniruberto, B.J. Kullberg, K. Lagrou, C. Le Bihan, R. Luzzati, M. Malbrain, M. Merelli, A.J. Marques, I. Martin-Loeches, A. Mesini, J.A. Paiva, M. Peghin, S.M. Raineri, R. Rautemaa-Richardson, J. Schouten, P. Brugnaro, H. Spapen, P. Tasioudis, J.F. Timsit, V. Tisa, M. Tumbarello, C. van den Berg, B. Veber, M. Venditti, G. Voiriot, J. Wauters, P. Montravers, Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project, Crit Care 23 (2019) 219. [CrossRef]
- Gouel-Cheron, B.J. Swihart, S. Warner, L. Mathew, J.R. Strich, A. Mancera, D. Follmann, S.S. Kadri, Epidemiology of ICU-Onset Bloodstream Infection: Prevalence, Pathogens, and Risk Factors Among 150,948 ICU Patients at 85 U.S. Hospitals, Crit Care Med 50 (2022) 1725-1736. [CrossRef]
- Logan, I. Martin-Loeches, T. Bicanic, Invasive candidiasis in critical care: challenges and future directions, Intensive Care Med 46 (2020) 2001-2014. [CrossRef]
- P. Hankovszky, D. Társy, N. Öveges, Z. Molnár, Invasive Candida Infections in the ICU: Diagnosis and Therapy, J Crit Care Med (Targu Mures) 1 (2015) 129-139. [CrossRef]
- V. Soulountsi, T. Schizodimos, S.C. Kotoulas, Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?, Infection 49 (2021) 1107-1131. [CrossRef]
- G. Aguilar, C. Delgado, I. Corrales, A. Izquierdo, E. Gracia, T. Moreno, E. Romero, C. Ferrando, J.A. Carbonell, R. Borrás, D. Navarro, F.J. Belda, Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study, BMC Res Notes 8 (2015) 491. [CrossRef]
- R.M. Schnabel, C.F. Linssen, N. Guion, W.N. van Mook, D.C. Bergmans, Candida pneumonia in intensive care unit?, Open Forum Infect Dis 1 (2014) ofu026. [CrossRef]
- P. Muñoz, M. Kestler, A. De Alarcon, J.M. Miro, J. Bermejo, H. Rodríguez-Abella, M.C. Fariñas, M. Cobo Belaustegui, C. Mestres, P. Llinares, M. Goenaga, E. Navas, J.A. Oteo, P. Tarabini, E. Bouza, Current Epidemiology and Outcome of Infective Endocarditis: A Multicenter, Prospective, Cohort Study, Medicine (Baltimore) 94 (2015) e1816. [CrossRef]
- G. Dimopoulos, F. Ntziora, G. Rachiotis, A. Armaganidis, M.E. Falagas, Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome, Anesth Analg 106 (2008) 523-529, table of contents. [CrossRef]
- B.M. Mac Curtain, A. O’Mahony, H.C. Temperley, Z.Q. Ng, Enhanced recovery after surgery protocols and emergency surgery: a systematic review and meta-analysis of randomized controlled trials, ANZ J Surg 93 (2023) 1780-1786. [CrossRef]
- S. Newton, B. Zollinger, J. Freeman, S. Moran, A. Helfand, K. Authelet, M. McHarg, N. Montano Vargas, R. Shesser, J.S. Cohen, D.A.T. Cummings, Y. Ma, A.C. Meltzer, Factors associated with clinical severity in emergency department patients presenting with symptomatic SARS-CoV-2 infection, J Am Coll Emerg Physicians Open 2 (2021) e12453. [CrossRef]
- Bartolo, V. Hall, N.D. Friedman, C. Lanyon, A. Fuller, C.O. Morrissey, E. Athan, Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports, BMC Infect Dis 21 (2021) 284. [CrossRef]
- J.I. Fonseca-Correa, R. Correa-Rotter, Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review, Frontiers in Medicine 8 (2021). [CrossRef]
- L.N. Ge, L. Wang, F. Wang, Effectiveness and Safety of Preoperative Oral Carbohydrates in Enhanced Recovery after Surgery Protocols for Patients with Diabetes Mellitus: A Systematic Review, Biomed Res Int 2020 (2020) 5623596. [CrossRef]
- R. Krause, B. Halwachs, G.G. Thallinger, I. Klymiuk, G. Gorkiewicz, M. Hoenigl, J. Prattes, T. Valentin, K. Heidrich, W. Buzina, H.J. Salzer, J. Rabensteiner, F. Prüller, R.B. Raggam, A. Meinitzer, C. Moissl-Eichinger, C. Högenauer, F. Quehenberger, K. Kashofer, I. Zollner-Schwetz, Characterisation of Candida within the Mycobiome/Microbiome of the Lower Respiratory Tract of ICU Patients, PLoS One 11 (2016) e0155033. [CrossRef]
- D.S. Meena, D. Kumar, Candida Pneumonia: An Innocent Bystander or a Silent Killer?, Med Princ Pract 31 (2022) 98-102. [CrossRef]
- J.K.T. Dermawan, S. Ghosh, M.K. Keating, K.V. Gopalakrishna, S. Mukhopadhyay, Candida pneumonia with severe clinical course, recovery with antifungal therapy and unusual pathologic findings: A case report, Medicine (Baltimore) 97 (2018) e9650. [CrossRef]
- M.S. Delisle, D.R. Williamson, M. Albert, M.M. Perreault, X. Jiang, A.G. Day, D.K. Heyland, Impact of Candida species on clinical outcomes in patients with suspected ventilator-associated pneumonia, Can Respir J 18 (2011) 131-136. [CrossRef]
- M. Albert, D. Williamson, J. Muscedere, F. Lauzier, C. Rotstein, S. Kanji, X. Jiang, M. Hall, D. Heyland, Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study), Intensive Care Med 40 (2014) 1313-1322. [CrossRef]
- P.G. Pappas, C.A. Kauffman, D.R. Andes, C.J. Clancy, K.A. Marr, L. Ostrosky-Zeichner, A.C. Reboli, M.G. Schuster, J.A. Vazquez, T.J. Walsh, T.E. Zaoutis, J.D. Sobel, Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America, Clin Infect Dis 62 (2016) e1-50. [CrossRef]
- Koulenti, M. Karvouniaris, E. Paramythiotou, N. Koliakos, N. Markou, P. Paranos, J. Meletiadis, S. Blot, Severe Candida infections in critically ill patients with COVID-19, J Intensive Med 3 (2023) 291-297. [CrossRef]
- Martin-Loeches, M. Antonelli, M. Cuenca-Estrella, G. Dimopoulos, S. Einav, J.J. De Waele, J. Garnacho-Montero, S.S. Kanj, F.R. Machado, P. Montravers, Y. Sakr, M. Sanguinetti, J.F. Timsit, M. Bassetti, ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients, Intensive Care Med 45 (2019) 789-805. [CrossRef]
- X. Tan, R. Chen, S. Zhu, H. Wang, D. Yan, X. Zhang, D. Farmakiotis, E. Mylonakis, Candida albicans Airway Colonization Facilitates Subsequent Acinetobacter baumannii Pneumonia in a Rat Model, Antimicrob Agents Chemother 60 (2016) 3348-3354. [CrossRef]
- Lanigan, J.F. Mailman, S. Kassir, K. Schmidt, S.B. Lee, E. Sy, Treatments and Outcomes of Critically Ill Patients with Candida spp. Colonization of the Lower Respiratory Tract in Regina, Saskatchewan, Can J Hosp Pharm 76 (2023) 309-313. [CrossRef]
- Huang, M. Qi, Y. Hu, M. Yu, Z. Liang, The impact of Candida spp airway colonization on clinical outcomes in patients with ventilator-associated pneumonia: A systematic review and meta-analysis, Am J Infect Control 48 (2020) 695-701. [CrossRef]
- Liu, L. Zhong, F. Zhou, C. Zheng, K. Zhang, J. Cai, H. Zhou, K. Tang, Z. Dong, W. Cui, G. Zhang, Clinical Features, Strain Distribution, Antifungal Resistance and Prognosis of Patients with Non-albicans Candidemia: A Retrospective Observational Study, Infect Drug Resist 14 (2021) 3233-3246. [CrossRef]
- M. Bassetti, A. Vena, R. Pincino, F. Briano, D.R. Giacobbe, Role of antifungal therapy in complicated intra-abdominal infections, Current Infectious Disease Reports 22 (2020) 1-8.
- S.S. Senger, G.R. Thompson, 3rd, P. Samanta, J. Ahrens, C.J. Clancy, M.H. Nguyen, Candida Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes, Open Forum Infect Dis 8 (2021) ofaa656. [CrossRef]
- C. Routsi, J. Meletiadis, E. Charitidou, A. Gkoufa, S. Kokkoris, S. Karageorgiou, C. Giannopoulos, D. Koulenti, P. Andrikogiannopoulos, E. Perivolioti, A. Argyropoulou, I. Vasileiadis, G. Vrioni, E. Paramythiotou, Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era, Antibiotics (Basel) 11 (2022). [CrossRef]
- V. Dias, Candida species in the urinary tract: is it a fungal infection or not?, Future Microbiol 15 (2020) 81-83. [CrossRef]
- M.S. Rishpana, J.S. Kabbin, Candiduria in Catheter Associated Urinary Tract Infection with Special Reference to Biofilm Production, J Clin Diagn Res 9 (2015) Dc11-13. [CrossRef]
- P. Behzadi, E. Behzadi, R. Ranjbar, Urinary tract infections and Candida albicans, Cent European J Urol 68 (2015) 96-101. [CrossRef]
- M.R. Yazdani, E. Foroughifar, R. Mohammadi, Identification of Candida Species Isolated from Renal Transplant Recipients with Candiduria, Int J Organ Transplant Med 7 (2016) 206-211.
- J. Marchena-Gomez, T. Saez-Guzman, M. Hemmersbach-Miller, A. Conde-Martel, V. Morales-Leon, A. Bordes-Benitez, M.A. Acosta-Merida, Candida isolation in patients hospitalized on a surgical ward: significance and mortality-related factors, World J Surg 33 (2009) 1822-1829. [CrossRef]
- J. Alves, C. Alonso-Tarrés, J. Rello, How to Identify Invasive Candidemia in ICU-A Narrative Review, Antibiotics (Basel) 11 (2022). [CrossRef]

| N (%) | ||
|---|---|---|
| A type of positive isolates | Urine cultures | 138 (58.5) |
| Tracheal aspirates | 94 (39.8) | |
| Blood cultures | 31 (13.1) | |
| Swabs from thoracic drains, abdominal cavity, cerebrospinal fluid | 29 (12.3) | |
| Wound cultures | 18 (7.6) | |
| Surveillance swabs | 1 (0.4) | |
| A total of positive samples | One sample | 137 (58.3) |
| ≥2 samples | 98 (41.7) | |
| Candida species (all patients) | albicans | 161 (68.2) |
| Non-albicans | 43 (18.2) | |
| ≥2 Candidas | 32 (13.6) | |
| Pathogenic bacteria associated with Candida at the time of sampling | 72 (30.5) | |
| Pre-COVID-19 vs. post-COVID-19* | All isolates | 154: 82 |
| Non-albicans | 40:35 | |
| Candida N=236) |
Control (N=261) |
Total | P | ||
|---|---|---|---|---|---|
| Age (years) | 66 (57 – 75) | 65(58 – 73) | 0.46* | ||
| Gender | Male | 132 (56) | 169 (65) | 301 (61) | 0.05† |
| Female | 104 (44) | 92 (35) | 196 (39) | ||
| Admission to the ICU | Elective | 23 (10) | 116 (44) | 139 (28) | <0.001† |
| Non-elective | 213 (90) | 145 (56) | 358 (72) | ||
| Outcome | Death | 99 (42) | 49 (19) | 148 (30) | <0.001† |
| Discharged | 134 (58) | 212 (81) | 346 (70) |
| Candida (N=236) | Control (N=261) | Difference | 95% CI of difference | P* | |
|---|---|---|---|---|---|
| ICU days | 9 (3 – 19) | 3 (2 – 6) | -5 | -6 do -3 | <0.001 |
| SAPS II on admission | 56 (43 – 68) | 45 (35 – 58) | -10 | -13 do -6 | <0.001 |
| SAPS II at discharge | 49 (30 – 79) | 33(26 – 45) | -12 | -16 do -7 | <0.001 |
| WBC on admission (x109/L) | 14.3 (9.9 – 20.8) | 13.4 (9.9 – 17.2) | -0.9 | -2.1 do 0.3 | 0.14 |
| CRP on admission [mg/L] | 162 (74 – 245) | 73 (20 – 168) | -65 | -90 do -43 | <0.001 |
| PCT on admission [mg/L] | 2.9 (1.3 – 17.8) | 1.3 (0.5 – 7.6) | -0.9 | -2.1 do -0.1 | 0.03 |
| Risk factors | ß | OR | 95% CI | P |
| Elective or non-elective admission | 1.52 | 4.55 | 2.59 - 7.99 | <0.001 |
| Age | 0.018 | 1.02 | 1.004 - 1.03 | 0.01 |
| SAPS II on admission | 0.043 | 1.04 | 1.03 - 1.06 | <0.001 |
| SAPS II at discharge | 0.124 | 1.13 | 1.11 - 1.16 | <0.001 |
| Isolation of Candida vs. control | 1.16 | 3.20 | 2.13 - 4.97 | <0.001 |
| Reoperation | 0.631 | 1.88 | 1.26 - 2.81 | 0.002 |
| Mechanical ventilation (hours) | 0.001 | 1.001 | 1.001 - 1.002 | <0.001 |
| Days of ICU | 0.017 | 1.02 | 1.004 - 1.03 | 0.01 |
| Comorbidities | ||||
| Heart diseases | 0.961 | 2.60 | 1.765 - 3.86 | <0.001 |
| Vascular diseases | 0.196 | 1.22 | 0.81 - 1.82 | 0.34 |
| Respiratory diseases | 0.481 | 1.62 | 1.09 - 2.38 | 0.02 |
| Coagulopathy | 0.673 | 1.96 | 1.11 - 3.47 | 0.02 |
| Poly/trauma | 0.002 | 1.002 | 0.58 - 1.74 | 0.99 |
| Neurological diseases | 0.165 | 1.18 | 0.80 - 1.75 | 0.41 |
| Renal diseases | 0.771 | 2.16 | 1.42 - 3.29 | <0.001 |
| Gastrointestinal diseases | 0.214 | 1.24 | 0.84 - 1.83 | 0.28 |
| Hepatobiliar diseases | 0.653 | 1.92 | 1.20 - 3.08 | 0.007 |
| Sepsis | 1.54 | 4.67 | 3.06 - 7.14 | <0.001 |
| Neoplasms | -0.95 | 0.39 | 0.25 - 0.59 | <0.001 |
| Metabolic diseases | 0.510 | 1.67 | 1.09 - 2.53 | 0.02 |
| Endocrine diseases | 0.143 | 1.15 | 0.75 - 1.78 | 0.52 |
| Psychiatric diseases | -0.077 | 0.93 | 0.56 - 1.52 | 0.76 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).